2023
Hepatitis B care cascade among people with HIV/HBV coinfection in the North American AIDS Cohort Collaboration on Research and Design, 2012–2016
Kim J, Newcomb C, Carbonari D, Torgersen J, Althoff K, Kitahata M, Klein M, Moore R, Reddy K, Silverberg M, Mayor A, Horberg M, Cachay E, Lim J, Gill M, Chew K, Sterling T, Hull M, Seaberg E, Kirk G, Coburn S, Lang R, McGinnis K, Gebo K, Napravnik S, Kim H, Re V, Research and Design of IeDEA F. Hepatitis B care cascade among people with HIV/HBV coinfection in the North American AIDS Cohort Collaboration on Research and Design, 2012–2016. PLOS ONE 2023, 18: e0290889. PMID: 37656704, PMCID: PMC10473492, DOI: 10.1371/journal.pone.0290889.Peer-Reviewed Original ResearchConceptsNorth American AIDS Cohort CollaborationUndetectable HBV DNAHBV coinfectionHBV DNACare cascadeCohort CollaborationViral suppressionHIV/HBV coinfectionTenofovir-based antiretroviral therapyHIV/HBVAntiretroviral therapy regimenCross-sectional studyDelivery of careHBV therapyHBV treatmentHBV viremiaAntiretroviral therapyHBV infectionHIV infectionTherapy regimenChronic infectionClinical cohortCoinfectionTherapyInfection
2015
Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study
Ahn J, Lee HM, Lim JK, Pan CQ, Nguyen MH, Kim W, Mannalithara A, Trinh H, Chu D, Tran T, Min A, Do S, Te H, Reddy KR, Lok AS. Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study. Alimentary Pharmacology & Therapeutics 2015, 43: 134-144. PMID: 26510638, PMCID: PMC4926997, DOI: 10.1111/apt.13440.Peer-Reviewed Original ResearchConceptsALT normalisationAdverse eventsHBV DNAHBeAg(-) patientsHBV patientsTreatment-naïve chronic hepatitis B patientsChronic hepatitis B patientsFive-year cumulative probabilityHBsAg loss/seroconversionLog 10 IU/Hepatitis B virus infectionEffectiveness of entecavirMedian HBV DNAUndetectable HBV DNAHepatitis B patientsB virus infectionAbnormal ALTEntecavir treatmentETV treatmentHBeAg lossHBsAg lossHepatic decompensationB patientsCohort studyMedian duration